![code on time win 10 error code on time win 10 error](https://www.stellarinfo.com/blog/wp-content/uploads/2020/06/How-to-Fix-Error-Code-0xc0000001.jpg)
He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. where he oversaw all licensing and acquisitions at Merck Research Laboratories. From 2011 to 2013, he was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. He currently serves as Chairman of the board of directors of Seres Therapeutics, and served as Chairman and CEO from June 2014 until January 2019. Pomerantz was appointed ContraFect’s Chief Executive Officer and Chairman of the board of directors in April of 2019, prior to which he served as Vice Chairman of the Company’s board of directors since May 2014. Russo received her PharmD and Bachelor of Science in Pharmacy from Rutgers University and holds a Board of Pharmacy Specialties Pharmacotherapy Certification (BCPS).Ĭhief Executive Officer and Chairman of the Boardĭr. She also held clinical positions at Robert Wood Johnson University Hospital and Princeton Hospital before joining the biotechnology industry. Russo held roles of increasing responsibility at Bristol-Myers Squibb where she started her industry career as a Postdoctoral Fellow in Industrial Pharmacy Infectious Diseases. Russo directly oversaw investigator-initiated research for a broad portfolio of anti-infectives, including daptomycin, fidaxomicin, ceftolozane/tazobactam, and tedizolid. In her role at Cubist, she was also responsible for the oversight of more than 140 studies designed to further understand Gram-positive and Gram-negative infections, including epidemiology, resistance patterns, and the study of various treatments (including combination therapies) across nonclinical and clinical studies. Russo oversaw the clinical microbiology program (including extensive in vitro and animal work to support dose selection and PK/PD analyses), contributed to the design of multiple Phase 1 to Phase 3 clinical studies, and directly managed the oversight of several global burden of disease programs, including urosepsis and nosocomial pneumonia, to understand the outcomes and unmet medical needs in these infectious diseases. As Vice President of an 80+ person global team, Dr. Russo served in various roles over an 11-year period at Cubist Pharmaceuticals (Cubist). Her work has spanned the earliest phases of in vitro and animal work to clinical pharmacology, clinical development, and post-marketing clinical outcomes research.
#Code on time win 10 error registration
René Russo, PharmD, BCPS, has spent more than 15 years in anti-infective R&D and has leadership experience across all phases of drug development, including global commercial launches for five novel antibacterial agents and clinical development and registration of several antiviral, antibacterial, and antifungal therapeutics. René Russo, PharmD, BCPS René Russo, PharmD, BCPS in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.
![code on time win 10 error code on time win 10 error](https://appuals.com/wp-content/uploads/2017/09/1-76.png)
![code on time win 10 error code on time win 10 error](https://cdn.windowsreport.com/wp-content/uploads/2021/07/Kernel-Security-Check-Failure.jpg)
Truong is the principal architect of Aridis’ technologies, which includes a range of anti-infective products and pharmaceutical processing technologies. His product development experience includes FluMist™, Synagis™ mAb and a number of other monoclonal antibody-based therapeutics. Having maintained a life-long interest in infectious diseases, he has focused on researching and developing innovative human monoclonal antibodies and vaccines designed to address life-threatening infections. He has more than 20 years of experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to MedImmune) and MedImmune (sold to Astra Zeneca). Truong is a founder of Aridis and was elected CEO in 2014 after having served as the company’s Chief Scientific Officer since 2005. Founder, Chief Executive Officer and Directorĭr.